Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial (Q46221067)

20 December 2017

title

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial (English)

1 reference

20 December 2017

1 reference

Gordon C Jayson

6

0 references

Anne Dørum

0 references

author name string

Gordon J S Rustin

1

1 reference

20 December 2017

Maria E L van der Burg

2

1 reference

20 December 2017

Clare L Griffin

3

1 reference

20 December 2017

David Guthrie

4

1 reference

20 December 2017

Alan Lamont

5

1 reference

20 December 2017

Gunnar Kristensen

7

1 reference

20 December 2017

César Mediola

8

1 reference

20 December 2017

Corneel Coens

9

1 reference

20 December 2017

Wendi Qian

10

1 reference

20 December 2017

Mahesh K B Parmar

11

1 reference

20 December 2017

Ann Marie Swart

12

1 reference

20 December 2017

MRC OV05

13

1 reference

20 December 2017

EORTC 55955 investigators

14

1 reference

20 December 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

20 December 2017

published in

The Lancet

1 reference

20 December 2017

volume

376

1 reference

20 December 2017

issue

9747

1 reference

20 December 2017

page(s)

1155-1163

1 reference

20 December 2017

Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a r

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961268-8

7 January 2021

Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961268-8

7 January 2021

Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961268-8

7 January 2021

Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961268-8

7 January 2021

A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961268-8

7 January 2021

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961268-8

7 January 2021

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961268-8

7 January 2021

Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961268-8

7 January 2021

Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961268-8

7 January 2021

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961268-8

7 January 2021

Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961268-8

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961268-8

7 January 2021

Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961268-8

7 January 2021

An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961268-8

7 January 2021

Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961268-8

7 January 2021

Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961268-8

7 January 2021

Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961268-8

7 January 2021

10.1016/S0140-6736(10)61268-8

Identifiers

DOI

1 reference

20 December 2017

PubMed ID

20888993

1 reference

20 December 2017